Stem cell trials for ms

Ginestal-Lopez RC. Immunotherapy for neurological diseases, present and future. Farm Hosp ; 42 Biomed Res Int ; Adv Biomed Res ; 7 Weiss JN, Levy S. Stem Cell Investig ; 6 ; Advising patients seeking stem cell interventions for multiple sclerosis. Pract Neurol ; 18 An update on intracerebral stem cell grafts. Expert Rev Neurother ; 18 Cold Spring Harb Perspect Med PLoS One ; 13 :e Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis.

Amelioration of experimental autoimmune encephalomyelitis through transplantation of placental derived mesenchymal stem cells. Sci Rep ; 7 Mesenchymal stem cell-based therapy in a mouse model of experimental autoimmune encephalomyelitis EAE. Methods Mol Biol ; The neuroprotective effect of mesenchymal stem cells on an experimentally induced model for multiple sclerosis in mice. J Biochem Mol Toxicol Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment.

Curr Neuropharmacol ; 9 Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med ; 78 Minagar A. Current and future therapies for multiple sclerosis. Scientifica Cairo ; Drug Class Reviews. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.

Mult Scler ; 23 COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. Br J Clin Pharmacol ; 82 Stem Cell Therapy for Multiple Sclerosis. Adv Exp Med Biol ; Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis. Int J Mol Sci ; 16 EBioMedicine ; 29 The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.

Adv Biomed Res ; 5 Biochem Genet ; 54 Cell-based therapy for idiopathic pulmonary fibrosis. Stem Cell Investig ; 6 Stem cells therapy: a review on approaches that can be used for treatment of respiratory failures in sulfur mustard-injured patients. Immunopharmacol Immunotoxicol ; 40 Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

PLoS One ; 9 :e Iran J Allergy Asthma Immunol ; 14 Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol ; 11 The mesenchymal stem cells in multiple sclerosis MSCIMS trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.

Trials ; 12 Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.

Arch Neurol ; 67 BMJ Open ; 5 :e Trials ; 16 Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant ; 47 Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models.

World J Stem Cells ; 7 Mediators Inflamm ; Cell J ; 19 Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS One ; 3 :e Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. Stem Cells Dev ; 22 Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis.

J Transl Med ; 16 Human placenta-derived cells PDA for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord ; 3 The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis.

Cell Transplant ; 23 Suppl 1 :S Transplantation of human fetal-derived neural stem cells improves cognitive function following cranial irradiation. Cell Transplant ; 23 Neural Plast ; Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med ; 1 Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.

J Neurol Sci ; Hatzimichael E, Tuthill M. Hematopoietic stem cell transplantation. Stem Cells Cloning ; 3 Front Immunol ; 9 Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.

Nat Rev Neurol ; 13 JAMA Neurol ; 74 Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality? Stem Cell Res Ther ; 7 Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.

JAMA ; Acta Haematol ; Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. Mult Scler ; 25 Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet ; T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

Immunology ; High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis HALT-MS : a 3-year interim report. JAMA Neurol ; 72 Shroff G. A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells. Stem Cells Cloning ; 11 Support Center Support Center. External link. Please review our privacy policy.

MSC therapy without side effect infusion. Incidence and severity of adverse events in MSC treatment group compared to placebo group. Detailed Description:. The endpoints to be considered in this study are: 2. MedlinePlus related topics: Multiple Sclerosis. FDA Resources. Arms and Interventions. After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen. Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex interferon beta 1a , Betaseron interferon beta 1b , Copaxone glatiramer acetate , Aubagio teriflunomide , Tysabri natalizumab , Gilenya fingolimod or Dimethyl fumarate Tecfidera or BG Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex interferon beta 1a , Betaseron interferon beta 1b , Copaxone glatiramer acetate , Aubagio teriflunomide , Tysabri natalizumab , or Gilenya fingolimod.

Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision.

Inclusion Criteria: Age between, inclusive. An EDSS score of 2. A steroid treated relapse will include a relapse that was severe enough to justify treatment but due to patient intolerance of steroids, or a history of non-response to steroids, they were offered but not used.

Prior history of malignancy except localized basal cell, squamous skin cancer or carcinoma in situ of the cervix. Other malignancies for which the patient is judged to be cured, such as head and neck cancer, or breast cancer will be considered on an individual basis.

Positive pregnancy test Inability or unwillingness to pursue effective means of birth control from the time of evaluation for eligibility until 6 months posttransplant if on transplant or until appropriate for non-transplant treatment if on control arm. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

National Library of Medicine U. Research at Vaccine Research Center. Clinical Research. Infectious Diseases. Resources for Researchers. Managing Symptoms. Understanding Triggers.

Autoimmune Diseases. Disease-Specific Research. Characterizing Disease. Researcher Resources. Dengue Fever. Shiga Toxin-Producing E. Researching Ebola in Africa. Photo Essay. Food Allergy. Research Approach. Treatment for Living with Food Allergy. Fungal Diseases. Group A Streptococcal Infections. Vaccine Research. Types of Group A Strep. Vaccine Development. Basic Research. Leprosy Hansen's Disease. Lyme Disease.

Antibiotic Treatment. Chronic Lyme Disease. Featured Research. Types of PIDDs. Talking to Your Doctor. Therapeutic Approaches. Animal Prion Diseases and Humans. Rocky Mountain Spotted Fever. Schistosomiasis Bilharzia. Tickborne Diseases. Tuberculosis Drugs. West Nile Virus. Addressing Zika Virus. Types of Funding Opportunities. See Funded Projects. Sample Applications. Determine Eligibility.

Prepare Your Application. Additional Application Elements. Research with Special Considerations.